Increased expression of SOCS2 in malignancies like chronic myeloid leukemia (CML) [219, 220] could contribute to transformation by negative interference with other SOCS molecules that normally would suppress tumor development. This evidence concerns the gene SOCS2 and chronic myelogenous leukemia, BCR-ABL1 positive.